Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection. Read more...
The FDA granted EUA for Eli Lilly and Company's investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Read more...
This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19. Read more...
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.